Skip to main content
Retour
ARDX logo

Ardelyx, Inc.

Qualité des données : 100%
Survendu
ARDX
NASDAQ Healthcare Biotechnology
5,31 €
0,00 € (0,00%)
Cap. Boursière : 1,30B
Fourchette du Jour
5,28 € 5,51 €
Fourchette 52 Semaines
3,21 € 8,40 €
Volume
3 830 071
Moyenne 50J / 200J
6,82 € / 5,67 €
Clôture Précédente
5,31 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -21,1 0,4
P/B 7,8 2,9
ROE % -36,2 3,8
Net Margin % -15,1 3,9
Rev Growth 5Y % 152,0 10,0
D/E 1,3 0,2

Objectif de Cours des Analystes

Hold
17,00 € +220.2%
Low: 15,00 € High: 19,00 €
P/E Prévisionnel
6637,5
BPA Prévisionnel
0,00 €
Croissance BPA (est.)
+0,0%
CA Est.
550 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 2,18 €
2,06 € – 2,28 €
1,4 B 5
FY2029 1,78 €
1,68 € – 1,86 €
1,2 B 2
FY2028 1,18 €
0,89 € – 1,63 €
980 M 7

Points Clés

Revenue grew 152,02% annually over 5 years — strong growth
Negative free cash flow of -43,98M
Revenue growth is decelerating — 1Y growth trails 5Y average by 129,93%
Capital efficient — spends only 0,37% of revenue on capex

Croissance

Revenue Growth (5Y)
152,02%
Revenue (1Y)22,09%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-36,21%
ROIC-8,12%
Net Margin-15,12%
Op. Margin-10,06%

Sécurité

Debt / Equity
1,27
Current Ratio4,31
Interest Coverage-1,44

Valorisation

P/E Ratio
-21,14
P/B Ratio7,80
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 22,09% Revenue Growth (3Y) 80,91%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 152,02% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 407,32M Net Income (TTM) -61,60M
ROE -36,21% ROA -12,28%
Gross Margin 90,29% Operating Margin -10,06%
Net Margin -15,12% Free Cash Flow (TTM) -43,98M
ROIC -8,12% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,27 Current Ratio 4,31
Interest Coverage -1,44 Dividend Yield 0,00%
Valuation
P/E Ratio -21,14 P/B Ratio 7,80
P/S Ratio 3,20 PEG Ratio -0,43
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,30B Enterprise Value 1,45B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 407,32M 333,62M 124,46M 52,16M 10,10M
Net Income -61,60M -39,14M -66,07M -67,21M -158,17M
EPS (Diluted) -0,26 -0,17 -0,30 -0,42 -1,52
Gross Profit 367,78M 283,06M 106,66M 48,04M 9,10M
Operating Income -40,98M -27,95M -63,28M -63,76M -154,35M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 501,60M 435,75M 297,58M 190,07M 149,91M
Total Liabilities 334,66M 262,47M 130,76M 91,74M 67,30M
Shareholders' Equity 166,95M 173,29M 166,82M 98,33M 82,62M
Total Debt 211,60M 153,44M 55,98M 36,46M 45,50M
Cash & Equivalents 68,00M 64,93M 21,47M 96,14M 72,43M
Current Assets 382,32M 356,45M 246,11M 153,60M 133,65M
Current Liabilities 88,61M 77,83M 50,39M 65,60M 52,82M